Article
Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.
mAbs - 1 Jan 2000
Mimoto Futa, Igawa Tomoyuki, Kuramochi Taichi, Katada Hitoshi, Kadono Shojiro, Kamikawa Takayuki, Shida-Kawazoe Meiri, Hattori Kunihiro
Abstract excerpt
Fc engineering is a promising approach to enhance the antitumor efficacy of monoclonal antibodies (mAbs) through antibody-dependent cell-mediated cytotoxicity (ADCC). Glyco- and protein-Fc engineering have been employed to enhance FcγR binding and ADCC activity of mAbs; the drawbacks of previous approaches lie in their binding affinity to both FcγRIIIa allotypes, the ratio of activating FcγR binding to inhibitory...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.